You are here
Evolus to Participate in Two Upcoming Investor Conferences
IRVINE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced today that members of management will be participating in two upcoming investor conferences.
|Event:||Stifel 2018 Healthcare Conference|
|Format:||Presentation & 1x1 Meetings|
|Date:||Tuesday, November 13, 2018|
|Time:||8:00 a.m. ET presentation|
|Location:||New York, NY|
|Event:||Jefferies 2018 London Healthcare Conference|
|Date:||Wednesday November 14 & Thursday, November 15, 2018|
An audio webcast of the Company’s presentation at the Stifel 2018 Healthcare Conference will be available on the investor relations section of Evolus’ website at investors.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.
Ashwin Agarwal, Evolus
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Kirsten Thomas, The Ruth Group
Dani Shaffer, Alison Brod Marketing + Communications